Tamoxifen and the risk of Parkinsonism: a case/non-case study.

HOME
>
論文・技術情報
>
Tamoxifen and the risk of Parkinsonism: a case/non-case study.

Tamoxifen and the risk of Parkinsonism: a case/non-case study.

アブストラクト	BACKGROUND: Three studies have suggested a potential positive association between the use of tamoxifen in breast cancer and Parkinsonism, mainly after long-term exposure. OBJECTIVES: To explore this potential signal, we performed a case/non-case study using the World Health Organization Global Individual Case Safety Reports (ICSRs) database, VigiBase(R) between 1979 and 2018. METHODS: Among women >/= 55 years, we measured the risk of reporting "Parkinsonism" compared with all other adverse drug reactions [as a reporting odds ratio (ROR 95% CI)] for tamoxifen compared to all other drugs or aromatase inhibitors. RESULTS: During the study period, 356 ICSRs of Parkinsonism reported with tamoxifen were identified. We failed to find a positive association between tamoxifen exposure and Parkinsonism in comparison with exposure to other drugs (ROR = 0.79; 95% CI 0.71-0.88) or aromatase inhibitors (ROR = 0.39; 95% CI 0.33-0.46). CONCLUSION: This study did not find evidence for Parkinsonism associated with tamoxifen.
ジャーナル名	European journal of clinical pharmacology
Pubmed追加日	2018/6/5
投稿者	Montastruc, Francois; Khosrow-Khavar, Farzin; de Germay, Sibylle; Renoux, Christel; Rousseau, Vanessa; Durrieu, Genevieve; Montastruc, Marion; Rascol, Olivier; Sommet, Agnes; Lapeyre-Mestre, Maryse; Benevent, Justine; Montastruc, Jean-Louis
組織名	Laboratoire de Pharmacologie Medicale et Clinique, Faculte de Medecine,;Universite de Toulouse, 37 allees Jules-Guesde, 31000, Toulouse, France.;Service de Pharmacologie Medicale et Clinique, Centre Hospitalier Universitaire;de Toulouse, Toulouse, France.;Centre Regional de PharmacoVigilance, de Pharmacoepidemiologie et d'Informations;sur le Medicament, Centre Hospitalier Universitaire de Toulouse, Toulouse,;France.;NeuroToul Centre of Excellence in Neurodegeneration, Centre Hospitalier;Universitaire de Toulouse, Toulouse, France.;Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital,;Montreal, Quebec, Canada.;Department of Epidemiology, Biostatistics, and Occupational Health, McGill;University, Montreal, Quebec, Canada.;INSERM UMR 1027, Faculte de Medecine de Toulouse, Universite de Toulouse,;Toulouse, France.;Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec,;Canada.;Institut Universitaire du Cancer Toulouse-Oncopole, 1 avenue Irene-Joliot-Curie,;31059, Toulouse, France.;CIC INSERM 1436, Centre Hospitalier Universitaire de Toulouse, Universite de;Toulouse, Toulouse, France.;jean-louis.montastruc@univ-tlse3.fr.;de Toulouse, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.;France. jean-louis.montastruc@univ-tlse3.fr.;Universitaire de Toulouse, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.;Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.;Toulouse, Toulouse, France. jean-louis.montastruc@univ-tlse3.fr.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/29862427/